ALT Q2 2024 Earnings — Altimmune, Inc. Revenue & Financial Results | Market Cap Arena

ALTAltimmune, Inc.

$353M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5,000-16.7% YoY

Gross Profit

$5,000100.0% margin

Operating Income

-$27M-534900.0% margin

Net Income

-$25M-492800.0% margin

EPS (Diluted)

$-0.35

QoQ Revenue Growth

+0.0%

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$18M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$173M

Total Liabilities

$21M

Stockholders' Equity

$153M

Cash & Equivalents

$57M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5,000	$6,000	-16.7%
Gross Profit	$5,000	-$13M	+100.0%
Operating Income	-$27M	-$18M	-48.5%
Net Income	-$25M	-$16M	-53.4%